Institute

O.C. Tanner's Meghan Stettler Recognized as One of Human Resources Director's Global 100 Leaders for the Second Consecutive Year

Retrieved on: 
Tuesday, November 15, 2022

SALT LAKE CITY, Nov. 15, 2022 /PRNewswire/ -- O.C. Tanner, the global leader in employee recognition and workplace culture, today announced that Meghan Stettler, a director at the O.C. Tanner Institute, has been named to this year's Human Resources Director (HRD) Global 100 list.

Key Points: 
  • Tanner , the global leader in employee recognition and workplace culture, today announced that Meghan Stettler, a director at the O.C.
  • Tanner Institute, has been named to this year's Human Resources Director (HRD) Global 100 list.
  • "I'm truly honored and grateful to be named among HRD's 100 most influential leaders two years running," said Stettler.
  • Tanner Institute team who consistently deliver market-leading research and insights to help organizations and their people thrive amid ongoing change.

Outlook on the EdTech and Smart Classrooms Global Market to 2028 - Featuring Microsoft, Cisco Systems, IBM and Google Among Others

Retrieved on: 
Tuesday, November 15, 2022

The Global EdTech and Smart Classrooms Market size is expected to reach $258.9 billion by 2028, rising at a market growth of 12.8% CAGR during the forecast period.

Key Points: 
  • The Global EdTech and Smart Classrooms Market size is expected to reach $258.9 billion by 2028, rising at a market growth of 12.8% CAGR during the forecast period.
  • Governments all over the world are issuing funding and grants to assist educational institutions in adopting cutting-edge teaching methods.
  • In addition, governments can thereby support the digitization of educational systems in their various areas and nations.
  • The market for digital classrooms is driven by the rising demand for digital education.

QuVa Pharma Introduces Innovative Two-Sided Labels for IV Bag Compounded Sterile Products

Retrieved on: 
Tuesday, November 15, 2022

SUGAR LAND, Texas, Nov. 15, 2022 /PRNewswire/ -- QuVa Pharma, Inc. announced today that is has developed a two-sided single label for its product portfolio of compounded IV bags. QuVa Pharma developed these new labels in consultation with its customers and in line with the Institute of Safe Medication Practices' (ISMP) 2022 best practice recommendations.

Key Points: 
  • SUGAR LAND, Texas, Nov. 15, 2022 /PRNewswire/ -- QuVa Pharma, Inc. announced today that is has developed a two-sided single label for its product portfolio of compounded IV bags.
  • QuVa Pharma developed these new labels in consultation with its customers and in line with the Institute of Safe Medication Practices' (ISMP) 2022 best practice recommendations.
  • Compounded Oxytocin IV bag product family will be the first to release with these new labels early in first quarter 2023, followed by all high-alert IV bag products like Fentanyl/Bupivacaine epidurals, Norepinephrine, Phenylephrine.
  • The remainder of compounded IV bag product families in QuVa's portfolio will follow throughout 2023.

4Cast Announces Partnership with SPIN Global, I-DIEM and IAEM for Emergency Decision-Making Tool Results to be Shared at EMEX 2022

Retrieved on: 
Tuesday, November 15, 2022

TEL AVIV, Israel, Nov. 15, 2022 /PRNewswire-PRWeb/ -- 4Cast, the leading developer of DI powered by AI platforms that support decision-making processes and optimize effectiveness, today announced its collaboration with SPIN Global, The Institute for Diversity and Inclusion in Emergency Management (I-DIEM), and the International Association of Emergency Management (IAEM). Together, they are forming a global initiative intended to shape the development of decision-making, enabling more equitable decisions before, during and after disasters.

Key Points: 
  • Together, they are forming a global initiative intended to shape the development of decision-making, enabling more equitable decisions before, during and after disasters.
  • Together, they are forming a global initiative intended to shape the development of decision-making, enabling more equitable decisions before, during and after disasters.
  • These pilots helped test and evaluate methods of utilizing AI in the context of emergency management planning, equity assessments, and workforce development.
  • We provide solutions focused on disaster resilience, risk reduction, emergency and crisis management for private industry, governments and communities.

America's Cutting Edge Celebrates 3000th Online Registrant

Retrieved on: 
Tuesday, November 15, 2022

 , Nov. 15, 2022 /PRNewswire/ -- "I'm 34 years old, this is my first job in manufacturing, and I'm really excited about my future!" said Marcus Beamon of Denton, Texas. America's Cutting Edge (ACE) is pleased to celebrate Marcus as the 3000th registrant for its free online machine training as a pathway toward a more fulfilling and prosperous career in manufacturing.

Key Points: 
  • America's Cutting Edge (ACE) is pleased to celebrate Marcus as the 3000th registrant for its free online machine training as a pathway toward a more fulfilling and prosperous career in manufacturing.
  • Both the 6-hour online course and the 32-hour in-person training require no prior experience and are offered at no cost.
  • ACE online has been most popular in Tennessee and North Carolina but is quickly gaining ground in the Lone Star State.
  • Mayday Manufacturing and Safran are two defense contractors that are sending numerous employees to pursue both the online and in-person training.

Metabolon Signs New Partnership with UK's Tracking Parkinson's Study

Retrieved on: 
Tuesday, November 15, 2022

MORRISVILLE, N.C., Nov. 15, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a new collaboration with Tracking Parkinson's, or the PRoBaND study, a UK-based longitudinal study of Parkinson's disease funded entirely by Parkinson's UK, to identify new metabolomic biomarkers and track biological changes over time to better understand Parkinson's disease pathogenesis.

Key Points: 
  • Since 2012, Tracking Parkinson's has collected clinical data and biosamples from more than 2,500 participants, recruited into three categories including recent onset, early onset, and participant siblings.
  • The study tracks participants for seven years and is one of the most clinically phenotyped cohorts globally.
  • This collaboration will allow Metabolon and Tracking Parkinson's to map metabolic changes in serum to clinical changes and genetic variants related to Parkinson's disease, allowing for the identification of novel biomarkers of disease progression.
  • It is extremely rewarding after so many years of data collection to realize that ambition through collaborations with teams like Metabolon.

Metabolon Signs New Partnership with UK's Tracking Parkinson's Study

Retrieved on: 
Tuesday, November 15, 2022

MORRISVILLE, N.C., Nov. 15, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a new collaboration with Tracking Parkinson's, or the PRoBaND study, a UK-based longitudinal study of Parkinson's disease funded entirely by Parkinson's UK, to identify new metabolomic biomarkers and track biological changes over time to better understand Parkinson's disease pathogenesis.

Key Points: 
  • Since 2012, Tracking Parkinson's has collected clinical data and biosamples from more than 2,500 participants, recruited into three categories including recent onset, early onset, and participant siblings.
  • The study tracks participants for seven years and is one of the most clinically phenotyped cohorts globally.
  • It is extremely rewarding after so many years of data collection to realize that ambition through collaborations with teams like Metabolon.
  • "We are extremely enthusiastic about partnering with Tracking Parkinson's to further the understanding of the pathogenesis of Parkinson's disease, said Karl Bradshaw, Vice President of Corporate Development at Metabolon.

Fourth Chinese Physicians Assembly for Humanity Launches First International Section on Evidence-based Medicine, Calls for Global Collaboration

Retrieved on: 
Tuesday, November 15, 2022

BEIJING, Nov. 15, 2022 /PRNewswire/ -- The Fourth Chinese Physicians Assembly for Humanity (CPAH) launched its first international section, inviting experts, doctors, and public welfare professionals from the United Kingdom, Norway, the Czech Republic, and other countries to share their insights on evidence-based medicine (EBM).

Key Points: 
  • BEIJING, Nov. 15, 2022 /PRNewswire/ -- The Fourth Chinese Physicians Assembly for Humanity (CPAH) launched its first international section, inviting experts, doctors, and public welfare professionals from the United Kingdom, Norway, the Czech Republic, and other countries to share their insights on evidence-based medicine (EBM).
  • This year's CPAH was held both online and offline on November 4-5, with the theme of Cohesion and Co-Construction: the Responsibilities of Physicians on Health-Care Welfare.
  • The online international section garnered over one million viewers worldwide.
  • The assembly advocated for a spirit of bravery and endeavors to unite public welfare physicians and healthcare enterprises to collaboratively build a new Great Wall of Health and Public Welfare.

Clarivate Names World's Influential Researchers with Highly Cited Researchers 2022 List

Retrieved on: 
Tuesday, November 15, 2022

LONDON, Nov. 15, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today revealed its 2022 list of Highly Cited Researchers™ – individuals at universities, research institutes and commercial organizations who have demonstrated a disproportionate level of significant and broad influence in their field or fields of research. The methodology draws on data from the Web of Science™ citation index, together with analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information (ISI)™ at Clarivate.

Key Points: 
  • This year Clarivate extended the qualitative analysis of the Highly Cited Researchers list, to address increasing concerns over potential misconduct (such as plagiarism, image manipulation, fake peer review).
  • With the assistance of Retraction Watch and its unparalleled database of retractions, Clarivate analysts searched for evidence of misconduct in all publications of those on the preliminary list of Highly Cited Researchers.
  • Researchers found to have committed scientific misconduct in formal proceedings conducted by a researcher's institution, a government agency, a funder or a publisher are excluded from the list of Highly Cited Researchers.
  • This is why we've expanded our qualitative analysis this year to ensure the Highly Cited Researchers list reflects genuine, community-wide research influence.

Clarivate Names World's Influential Researchers with Highly Cited Researchers 2022 List

Retrieved on: 
Tuesday, November 15, 2022

LONDON, Nov. 15, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today revealed its 2022 list of Highly Cited Researchers™ – individuals at universities, research institutes and commercial organizations who have demonstrated a disproportionate level of significant and broad influence in their field or fields of research. The methodology draws on data from the Web of Science™ citation index, together with analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information (ISI)™ at Clarivate.

Key Points: 
  • This year Clarivate extended the qualitative analysis of the Highly Cited Researchers list, to address increasing concerns over potential misconduct (such as plagiarism, image manipulation, fake peer review).
  • With the assistance of Retraction Watch and its unparalleled database of retractions, Clarivate analysts searched for evidence of misconduct in all publications of those on the preliminary list of Highly Cited Researchers.
  • Researchers found to have committed scientific misconduct in formal proceedings conducted by a researcher's institution, a government agency, a funder or a publisher are excluded from the list of Highly Cited Researchers.
  • This is why we've expanded our qualitative analysis this year to ensure the Highly Cited Researchers list reflects genuine, community-wide research influence.